Ocular Therapeutix (OCUL) Total Liabilities (2013 - 2026)
Ocular Therapeutix's quarterly Total Liabilities came in at $151.0 million in Q1 2026, up 7.83% year-on-year from $140.0 million in Q1 2025, and down 1.82% quarter-over-quarter from $153.7 million in Q4 2025.
Ocular Therapeutix has reported Total Liabilities for 14 years, with the latest figure at $151.0 million in Q1 2026.
- For the quarter ending Q1 2026, Total Liabilities rose 7.83% year-over-year to $151.0 million; the trailing twelve-month figure through Mar 2026 stood at $151.0 million (up 7.83% YoY), and the FY2025 full-year result was $153.7 million, up 7.82% from the prior year.
- Total Liabilities for Q1 2026 stood at $151.0 million, down from $153.7 million in the prior quarter.
- The five-year high for Total Liabilities was $160.9 million in Q4 2023, with the low at $107.3 million in Q2 2022.
- Average Total Liabilities over 5 years is $134.7 million, with a median of $139.4 million recorded in 2024.
- Year-over-year, Total Liabilities tumbled 32.45% in 2022 and surged 41.28% in 2023.
- Tracing OCUL's Total Liabilities over 5 years: stood at $113.9 million in 2022, then surged by 41.28% to $160.9 million in 2023, then retreated by 11.4% to $142.6 million in 2024, then grew by 7.82% to $153.7 million in 2025, then dropped by 1.82% to $151.0 million in 2026.
- The last three Total Liabilities figures came in at $151.0 million (Q1 2026), $153.7 million (Q4 2025), and $152.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.74 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 731.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 177.22 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 19.51 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 7.12 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 10.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 9.45 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Ocular Therapeutix | 1.99 Bn | 1.99 Bn | 9.46 Mn | 150.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 150.96 Mn |
| Dec 31, 2025 | 153.75 Mn |
| Sep 30, 2025 | 152.65 Mn |
| Jun 30, 2025 | 145.42 Mn |
| Mar 31, 2025 | 139.99 Mn |
| Dec 31, 2024 | 142.59 Mn |
| Sep 30, 2024 | 138.35 Mn |
| Jun 30, 2024 | 139.40 Mn |
| Mar 31, 2024 | 130.96 Mn |
| Dec 31, 2023 | 160.93 Mn |
| Sep 30, 2023 | 154.53 Mn |
| Jun 30, 2023 | 119.47 Mn |
| Mar 31, 2023 | 118.86 Mn |
| Dec 31, 2022 | 113.91 Mn |
| Sep 30, 2022 | 112.35 Mn |
| Jun 30, 2022 | 107.27 Mn |
| Mar 31, 2022 | 107.83 Mn |
| Dec 31, 2021 | 116.89 Mn |
| Sep 30, 2021 | 130.40 Mn |
| Jun 30, 2021 | 150.46 Mn |
| Mar 31, 2021 | 159.63 Mn |
| Dec 31, 2020 | 185.77 Mn |
| Sep 30, 2020 | 102.35 Mn |
| Jun 30, 2020 | 101.92 Mn |
| Mar 31, 2020 | 83.52 Mn |
| Dec 31, 2019 | 82.37 Mn |
| Sep 30, 2019 | 77.41 Mn |
| Jun 30, 2019 | 81.48 Mn |
| Mar 31, 2019 | 75.84 Mn |
| Dec 31, 2018 | 37.17 Mn |
| Sep 30, 2018 | 24.75 Mn |
| Jun 30, 2018 | 24.73 Mn |
| Mar 31, 2018 | 27.50 Mn |
| Dec 31, 2017 | 29.28 Mn |
| Sep 30, 2017 | 28.48 Mn |
| Jun 30, 2017 | 31.65 Mn |
| Mar 31, 2017 | 26.79 Mn |
| Dec 31, 2016 | 22.93 Mn |
| Sep 30, 2016 | 20.05 Mn |
| Jun 30, 2016 | 19.45 Mn |
| Mar 31, 2016 | 20.26 Mn |
| Dec 31, 2015 | 20.72 Mn |
| Sep 30, 2015 | 20.51 Mn |
| Jun 30, 2015 | 20.36 Mn |
| Mar 31, 2015 | 19.42 Mn |
| Dec 31, 2014 | 19.50 Mn |
| Sep 30, 2014 | 18.28 Mn |
| Jun 30, 2014 | 19.05 Mn |
| Dec 31, 2013 | 4.27 Mn |